Skip to main content
Top
Published in: International Journal of Clinical Oncology 2/2013

01-04-2013 | Introduction to Review Articles

Recent advances in research on epigenetic alterations and clinical significance of para-aortic lymphadenectomy in endometrial cancer: an introduction

Author: Noriaki Sakuragi

Published in: International Journal of Clinical Oncology | Issue 2/2013

Login to get access

Excerpt

Endometrial cancer is the most frequent cancer of the female reproductive organs in industrialized countries. In 2012, the numbers of new cases and deaths from endometrial cancer in the US were estimated to be 47,130 and 8,010, respectively [1]. The incidence of endometrial cancer is also increasing steadily in Japan, where the estimated number of new cases in 2007 was 9,104 [2] and the number of deaths in 2011 was 2,034 [3]. Endometrial cancer is a surgically staged disease and post-operative therapy is offered to patients with a high risk of recurrence according to the extent and aggressiveness of the tumor. Current topics in endometrial cancer include: the therapeutic significance of lymphadenectomy, the role of epigenetic alterations, and revision of the International Federation of Gynecology and Obstetrics staging criteria (FIGO 2008) for this disease. …
Literature
4.
go back to reference Look K (2002) Stage I-II endometrial adenocarcinoma evolution of therapeutic paradigms: the role of surgery and adjuvant radiation. Int J Gynecol Cancer 12:237–249 (Review)PubMedCrossRef Look K (2002) Stage I-II endometrial adenocarcinoma evolution of therapeutic paradigms: the role of surgery and adjuvant radiation. Int J Gynecol Cancer 12:237–249 (Review)PubMedCrossRef
5.
go back to reference Lewis BV (1964) Nodal spread in relation to penetration and differentiation. Proc Roy Soc Med 64:406–407 Lewis BV (1964) Nodal spread in relation to penetration and differentiation. Proc Roy Soc Med 64:406–407
6.
go back to reference Cragun JM, Havrilesky LJ, Calingaert B et al (2005) Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 23:3668–3675PubMedCrossRef Cragun JM, Havrilesky LJ, Calingaert B et al (2005) Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 23:3668–3675PubMedCrossRef
7.
go back to reference Chan JK, Cheung MK, Huh WK et al (2006) Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 107:1823–1830PubMedCrossRef Chan JK, Cheung MK, Huh WK et al (2006) Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 107:1823–1830PubMedCrossRef
8.
go back to reference Mariani A, Webb MJ, Galli L et al (2000) Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol 76:348–356PubMedCrossRef Mariani A, Webb MJ, Galli L et al (2000) Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol 76:348–356PubMedCrossRef
9.
go back to reference Benedetti Panici P, Basile S, Maneschi F et al (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716PubMedCrossRef Benedetti Panici P, Basile S, Maneschi F et al (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716PubMedCrossRef
10.
go back to reference ASTEC Study Group (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomized study. Lancet 373:125–136CrossRef ASTEC Study Group (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomized study. Lancet 373:125–136CrossRef
11.
go back to reference Todo Y, Kato H, Kaneuchi M et al (2010) Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL Study): a retrospective cohort analysis. Lancet 375:1165–1172PubMedCrossRef Todo Y, Kato H, Kaneuchi M et al (2010) Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL Study): a retrospective cohort analysis. Lancet 375:1165–1172PubMedCrossRef
12.
go back to reference van der Linden W (1980) Pitfalls in randomized surgical trials. Surgery 87:258–262PubMed van der Linden W (1980) Pitfalls in randomized surgical trials. Surgery 87:258–262PubMed
13.
go back to reference Bonchek LI (1997) Randomised trials of new procedures: problems and pitfalls. Heart 78:535–536PubMed Bonchek LI (1997) Randomised trials of new procedures: problems and pitfalls. Heart 78:535–536PubMed
14.
go back to reference McCulloch P, Taylor I, Sasako M et al (2002) Randomised trials in surgery: problems and possible solutions. BMJ 324:1448–1451PubMedCrossRef McCulloch P, Taylor I, Sasako M et al (2002) Randomised trials in surgery: problems and possible solutions. BMJ 324:1448–1451PubMedCrossRef
15.
go back to reference Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. N Engl J Med 342:1878–1886PubMedCrossRef Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. N Engl J Med 342:1878–1886PubMedCrossRef
16.
go back to reference Concato J, Shah N, Horwitz RI (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342:1887–1892PubMedCrossRef Concato J, Shah N, Horwitz RI (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342:1887–1892PubMedCrossRef
17.
18.
go back to reference Lax SF, Kurman RJ (1997) A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol 81:228–232 (Review)PubMed Lax SF, Kurman RJ (1997) A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol 81:228–232 (Review)PubMed
19.
go back to reference Alvarez T, Miller E, Duska L et al (2012) Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Am J Surg Pathol 36:753–761PubMedCrossRef Alvarez T, Miller E, Duska L et al (2012) Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Am J Surg Pathol 36:753–761PubMedCrossRef
20.
go back to reference Voss MA, Ganesan R, Ludeman L et al (2012) Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer—a clinical and pathological evaluation. Gynecol Oncol 124:15–20PubMedCrossRef Voss MA, Ganesan R, Ludeman L et al (2012) Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer—a clinical and pathological evaluation. Gynecol Oncol 124:15–20PubMedCrossRef
21.
go back to reference Sakuragi N, Watari H, Ebina Y et al (2005) Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer. Int J Cancer 116:514–519PubMedCrossRef Sakuragi N, Watari H, Ebina Y et al (2005) Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer. Int J Cancer 116:514–519PubMedCrossRef
22.
go back to reference Lee EJ, Kim TJ, Kim DS et al (2010) p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. Gynecol Oncol 116:533–538PubMedCrossRef Lee EJ, Kim TJ, Kim DS et al (2010) p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. Gynecol Oncol 116:533–538PubMedCrossRef
23.
go back to reference Hiroki E, Suzuki F, Akahira J et al (2012) MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. Int J Cancer 131:E395–E404PubMedCrossRef Hiroki E, Suzuki F, Akahira J et al (2012) MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. Int J Cancer 131:E395–E404PubMedCrossRef
24.
go back to reference Nagase S, Katabuchi H, Hiura M, Japan Society of Gynecologic Oncology et al (2010) Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition. Int J Clin Oncol 15:531–542PubMedCrossRef Nagase S, Katabuchi H, Hiura M, Japan Society of Gynecologic Oncology et al (2010) Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition. Int J Clin Oncol 15:531–542PubMedCrossRef
25.
go back to reference Uterine neoplasms. NCCN clinical practice guidelines in oncology, version 3.2012. NCCN.org Uterine neoplasms. NCCN clinical practice guidelines in oncology, version 3.2012. NCCN.org
26.
go back to reference Iwatsuki M, Mimori K, Yokobori T et al (2010) Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 101:293–299 (Review)PubMedCrossRef Iwatsuki M, Mimori K, Yokobori T et al (2010) Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 101:293–299 (Review)PubMedCrossRef
27.
go back to reference Murakami A, Yakabe K, Yoshidomi K et al (2012) Decreased carbonyl reductase 1 expression promotes malignant behaviours by induction of epithelial mesenchymal transition and its clinical significance. Cancer Lett 323:69–76PubMedCrossRef Murakami A, Yakabe K, Yoshidomi K et al (2012) Decreased carbonyl reductase 1 expression promotes malignant behaviours by induction of epithelial mesenchymal transition and its clinical significance. Cancer Lett 323:69–76PubMedCrossRef
28.
go back to reference Dong P, Kaneuchi M, Watari H et al (2011) MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 10:99. doi: 10.1186/1476-4598-10-99 Dong P, Kaneuchi M, Watari H et al (2011) MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 10:99. doi: 10.​1186/​1476-4598-10-99
29.
go back to reference Dong P, Karaayvaz M, Jia N et al (2012) Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b–ZEB1 axis. Oncogene. doi: 10.1038/onc.2012.334. (Epub ahead of print) Dong P, Karaayvaz M, Jia N et al (2012) Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b–ZEB1 axis. Oncogene. doi: 10.​1038/​onc.​2012.​334. (Epub ahead of print)
30.
go back to reference Umene K, Banno K, Kisu I et al (2013) New candidate therapeutic agents for endometrial cancer: potential for clinical practice. Oncol Rep. 29:855–860 (Review)PubMed Umene K, Banno K, Kisu I et al (2013) New candidate therapeutic agents for endometrial cancer: potential for clinical practice. Oncol Rep. 29:855–860 (Review)PubMed
Metadata
Title
Recent advances in research on epigenetic alterations and clinical significance of para-aortic lymphadenectomy in endometrial cancer: an introduction
Author
Noriaki Sakuragi
Publication date
01-04-2013
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-013-0535-8

Other articles of this Issue 2/2013

International Journal of Clinical Oncology 2/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine